最近关于慢性移植对宿主病单克隆抗体的进展和研究进展
Shiqin Huang1,2,3, Xianjing Cheng1,2,3, Guancui Yang1,2,3
1Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037 China.
Heliyon
|October 15, 2024
概括
单克隆抗体 (mAbs) 在干细胞移植后有望预防和治疗慢性移植对宿主疾病 (cGVHD). 本综述探讨了目前mAb的使用情况以及cGVHD.cGVHD的潜在自身免疫性疾病药物应用.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 慢性移植对宿主疾病 (cGVHD) 是异构造血型干细胞移植 (HSCT) 后死亡的主要原因.
- 像皮质类固醇这样的传统治疗方法的疗效有限,只有50%的患者有反应.
- 单克隆抗体 (mAbs) 代表了cGVHD管理的重大进展.
研究的目的:
- 提供关于mAb用于cGVHD预防和治疗的最新临床发展的全面概述.
- 探索针对自身免疫性疾病中cGVHD相关部位的药物作为未来cGVHD疗法的潜力.
- 为优化cGVHD治疗策略和研究方向提供见解.
主要方法:
- 对cGVHD.cGVHD中的mAbs临床研究的文献综述.
- 鉴定用于自身免疫性疾病的药物,这些药物具有与cGVHD相关的共同点.
- 综合当前的证据和未来的治疗可能性.
主要成果:
- 单克隆抗体 (mAbs),包括CD20 mAbs,在一线cGVHD治疗中表现出高于皮质类固醇的疗效.
- 最近的进展凸显了mAbs在预防和治疗cGVHD中的日益增长的临床应用.
- 针对自身免疫性疾病相关途径的药物显示出未来cGVHD治疗策略的潜力.
结论:
- 单克隆抗体是治疗慢性移植对宿主疾病的一个有前途的治疗类.
- 探索自身免疫性疾病的治疗方法为未来的cGVHD疗法提供了新的途径.
- 对mAb应用和跨学科药物发现的持续研究对于改善cGVHD结果至关重要.
更多相关视频
10:29Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
Published on: August 29, 2012
15.7K
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
14.5K
相关概念视频
01:31Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
01:40Cell-mediated Immune Responses
67.5K
Overview
67.5K
01:22Bone Marrow Sampling and Transplants
312
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
312